Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement

Press ReleaseNicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement Option entitles Glaukos to exclusive global license agreements on pre-agreed terms including upfront and milestone payments plus royaltiesGlaukos to fund and conduct NCX 1728 preclinical research activities evaluating it in glaucoma (including neuroprotection) and in other retinal diseasesNicox focused on continued Phase 3 development of lead drug-candidate, NCX 470...

Biot, 23/09/2024 (informazione.it - comunicati stampa - salute e benessere)

Attachment